STOCKHOLM – 27. of March 2019 – ContextVision, a medical technology company specializing in image analysis and artificial intelligence, is pleased to announce that Fredrik Palm will become CEO of the Company as of April 1, 2019. Fredrik Palm has since 2012 been the Company’s V.P. of sales and was instrumental in growing sales significantly under his tenure. Fredrik Palm will succeed Anita Tollstadius, who in October 2018 announced her intent and wish to step down to dedicate more time to her family.
“We are very pleased that an experienced industry executive like Fredrik Palm will become our new CEO and lead the Company into what we expect to become a transformational and exciting period for the Company going forward. We are now positioning the Company to become a world leader within Digital Pathology with our first product now expected close to market introduction. Fredrik’s experience, vision and strong leadership will be extremely valuable to the Company during this period as many of our concept products become ready for the market”, says chairman Erik Danielsen.
“I am humble, but also ready for the tasks that stand before me. The whole team here at ContextVision has done a remarkable job in recent years, which has not only resulted in record sales within medical imaging, but also in developing a ground-breaking product for digital pathology based on artificial intelligence. I believe this, and future products, are well positioned to capitalize on a large market opportunity as healthcare services become more and more digital”, says Fredrik Palm.
“We want to thank Anita Tollstadius for her leadership and many achievements as CEO of ContextVision over the last 9 years. She has built a strong organization and created a corporate culture that is focused on innovation and the development of next-generation products. This, in addition, to ensuring that the Company’s existing Imaging Enhancement business has continued to grow profitably, thus leaving the Company well positioned for the future”, says Danielsen.
“It has been a fantastic journey, both for me and the entire ContextVision team, and I am incredibly proud of what we have achieved togehter. I wish Fredrik and the rest of the team all the best for what I believe will be both an exciting and successful future!”, says Anita Tollstadius.
Fredrik Palm has over 20 years of experience from companies within life science, where he has mainly worked from the marketing and sales side in a global perspective. Since 2012, he has led the marketing and sales activities at ContexVision, where revenue during the period has increased from SEK 60 million to more than SEK 90 million last year.
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
This information is information that ContextVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on March 27, 2019.
For further information, please contact Fredrik Palm, cell: +46 76 870 25 43, E-mail:
About ContextVision
ContextVision is a medical technology software company that specializes in image analysis and artificial intelligence. As the global market leader within image enhancement, ContextVision is a software partner to leading medical imaging manufacturers around the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
As an industry pioneer for more than 30 years, ContextVision has developed state-of-the-art capabilities in the latest artificial intelligence technologies. By combining these with its well-established GOP technology, the company is introducing a new generation of image enhancement products. ContextVision is also approaching the growing digital pathology market with new AI-based decision support tools for pathologists.
The company is based in Sweden, with local representation in the U.S., Russia, Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange under the ticker COV.